Evidence map›Paper›PMID 36874443›Full record

ArticleGlobal heart2023

Access to Essential Medicines and Diagnostic Tests for Cardiovascular Diseases in Maputo City, Mozambique.

Neusa Jessen, Abhishek Sharma, Jennifer Jones, Tangeni Auala, Sainimere Boladuadua, Ahmadou Jingi, Jose Ferrer, Ana Olga Mocumbi

Abstract read
In one paragraph

Article in Global heart, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. May Measurement Month 2022: an analysis of blood pressure screening results from Mozambique.European heart journal supplements : journal of the European Society of Cardiology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Neusa JessenWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0002-6304-7557
Abhishek SharmaWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0001-8561-6194
Jennifer JonesWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0001-8388-9025
Tangeni AualaWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0002-6418-1301
Sainimere BoladuaduaWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0002-0768-0454
Ahmadou JingiWorld Heart Federation, Geneva, Switzerland.
Jose FerrerWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0003-2999-7687
Ana Olga MocumbiWorld Heart Federation, Geneva, Switzerland.ORCID 0000-0002-9564-2860

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: To tackle the increasing burden of non-communicable diseases (NCDs) and reduce premature cardiovascular (CV) mortality by a third by the year 2030, countries must achieve 80% availability of affordable essential medicines (EMs) and technologies in all health facilities. Objectives: To evaluate access to EMs and diagnostics for CV diseases in Maputo City, Mozambique. Methods: Using a modified version of World Health Organization (WHO)/Health Action International (HAI) methodology, we collected data on availability and price of 14 WHO Core EMs and 35 CV EMs in all 6 public-sector hospitals, 6 private-sector hospitals, and 30 private-retail pharmacies. Data on 19 tests and 17 devices were collected from hospitals. Medicine prices were compared with international reference prices (IRPs). Medicines were considered unaffordable if the lowest paid worker had to spend more than one day's wage to purchase a monthly supply. Results: Mean availability of CV EMs was lower than that of WHO Core EMs in both public (hospitals: 20.7% vs. 52.6%) and private sectors (retail pharmacies: 21.5% vs. 59.8%; hospitals: 22.2% vs. 50.0%). Mean availability of CV diagnostic tests and devices was lower in public (55.6% and 58.3%, respectively) compared to private sector (89.5% and 91.7%, respectively). Across WHO Core and CV EMs, the median price of lowest priced generic (LPG) and most sold generic (MSG) versions were 4.43 and 3.20 times the IRP, respectively. Relative to the IRP, median price of CV medicines was higher than that of Core EMs (LPG: 4.51 vs. 2.93). The lowest paid worker would spend 14.0 to 17.8 days' wage monthly to undergo secondary prevention. Conclusion: Access to CV EMs is limited in Maputo City owing to low availability and poor affordability. Public-sector hospitals are not well equipped with essential CV diagnostics. This data could inform evidence-based policies for improving access to CV care in Mozambique.

Indexed as

Cardiovascular AgentsCardiovascular DiseasesDiagnostic Tests, RoutineDrugs, GenericHospitalsHumansMozambiqueCardiovascular AgentsDrugs, Genericcardiovascular diagnosticscardiovascular medicinesessential medicinesMaputoMozambique

Identifiers

PMID36874443
PMCPMC9983496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.